Reading this on a mobile device? Try our optimized mobile version here:

March 6, 2013News for the transfusion medicine and cellular therapy community

  Top Story 
  • CDC warns of deadly, antibiotic-resistant bacteria
    CDC data show that in the first half of 2012, 4% of U.S. hospitals and 18% of nursing homes had at least one case of carbapenem-resistant Enterobacteriaceae, a family of deadly bacteria resistant to even the strongest antibiotics. The CDC urged facilities to stop the spread of the bacteria by enforcing infection-control policies, grouping CRE patients together, alerting hospitals when these patients are transferred and using antibiotics judiciously. USA Today (3/5), HealthDay News (3/5), The Washington Post (3/5) LinkedInFacebookTwitterEmail this Story
Quality and Process Improvement Solutions are Just a Click Away
AABB Consulting Services can help you meet the requirements of any accrediting organization. Guidance is also available for: implementation plans, process flow, software issues, computer validation, compliance audits, vendor audits and custom projects. For more information, visit our web site or email

  Science & Health 
  • Method could prevent GVHD in bone marrow transplants
    Blocking the Notch signaling pathway in donor cells may reduce the risk of graft-versus-host disease after bone marrow transplants, a University of Michigan team reports in the Journal of Clinical Investigation. Targeting a ligand-receptor pair in the Notch signaling pathway prevented the disease in mice and did not cause adverse effects or affect the ability of the transplanted cells to fight cancer, according to the study. The findings open new routes for possible treatments of T cell-related conditions in transplants, an investigator said. Genetic Engineering & Biotechnology News (3/1) LinkedInFacebookTwitterEmail this Story
  • Researchers study use of cell signal in delaying stem cell aging
    Researchers at Georgia Regents University are assessing the potential use of a cell signal called stromal derived factor-1 in improving stem cell survival and staving off cell aging. Researchers modified cells to generate more than the normal levels of SDF-1 and found that this increased cell survival after transplant. The approach could potentially treat damaged bones and osteoporosis. The researchers plan to test the approach in older and younger orthopedic patients. The Augusta Chronicle (Ga.) (3/5) LinkedInFacebookTwitterEmail this Story
  • Nanoparticles could aid fast test for infectious diseases
    A screening method that uses DNA powder and gold nanoparticles has passed tests involving the identification of malaria and sexually transmitted diseases, researchers at the University of Toronto's Institute of Biomaterials and Biomedical Engineering reported in the journal Angewandte Chemie. The test is being developed as a fast point-of-care assay for the diagnosis of multiple infections from a single small sample. (3/5) LinkedInFacebookTwitterEmail this Story
  Emerging Trends 
  • Poor compliance hinders HIV-prevention regimen in African trial
    A study in southern Africa found that the use of tablets and vaginal gels did not prevent the spread of HIV due to inconsistent compliance with the regimens. "We need to rethink the design of these intervention trials ... in healthy people because it is difficult for anybody to take a pill or anything every day, particularly when you are healthy and do not feel that you need a drug," researcher Jeanne Marrazzo said. Reuters (3/4) LinkedInFacebookTwitterEmail this Story
  Industry News & Practice 

On-line SBB Exam Review Course offered through The George Washington University
Self-paced preparation for the ASCP SBB certification exam. Application deadlines: February 1, June 1 and September 1. Main exam content categories covered. Includes sample exam questions. Contact course director, William Turcan, at for more information.

  Government & Regulatory 
  • White House to Congress: Exempt FDA user fees from sequester
    The Obama administration urged Congress to allow the FDA to spend $41 billion in drugmaker user fees the agency has collected. The sequestration law limits the amount of fee-derived funds that the FDA can spend, and experts warn that the agency will not be able to approve new drug and device applications quickly if the funds are subject to sequestration. The White House warned sequestration will slow progress toward cures and cost thousands of researchers their job. PharmaTimes (U.K.) (3/5), The Philadelphia Inquirer (2/28) LinkedInFacebookTwitterEmail this Story
  Association News 
  • AABB submits comments on draft guidance for preclinical assessment of cellular and gene therapies
    AABB has submitted comments to the FDA on the draft guidance for industry titled "Preclinical Assessment of Investigational Cellular and Gene Therapy Products." Comments were developed based on feedback the association collected from AABB member cellular therapy experts. Individuals with questions regarding these comments may contact Rafael Cassata, MS, RAC (US, EU), a deputy director in AABB's Regulatory Affairs department. LinkedInFacebookTwitterEmail this Story
Learn more about AABB® ->Homepage  |  Join AABB  |  Conferences  |  Marketplace

Position TitleCompany NameLocation
Cord Blood Laboratory ManagerPuget Sound Blood CenterUS - WA - Seattle
IRL Clinical Lab ManagerBlood Systems LaboratoriesUS - AZ - Tempe
Assistant Medical DirectorLifeStreamUS - CA
Director, Technical ServicesUnited Blood ServicesUS - NV - Reno
Supervisor of Blood Donor ServicesBaystate HealthUS - MA - Springfield
Click here to view more job listings.

Every time you spend money, you're casting a vote for the kind of world you want."
--Anna Lappé,
American writer, speaker and activist

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Corporate Relations Manager:  Tamara Zein (240) 333-6604
Job Board: AABB CareerLink
A powerful website for SmartBrief readers including:
 Recent AABB SmartBrief Issues:   Lead Editor:  Tom Parks
Managing Editor: Jennifer Garfinkel

Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2013 SmartBrief, Inc.® Legal Information